

Active substances set

Search phrase: odronextamab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Odronextamab

Odronextamab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.



NO REIMBURSEMENT



ESMO